{"schema_version":"secwatch.filing_event.v1","accession":"0001477932-23-001496","form_type":"8-K","ticker":"VNRX","cik":"0000093314","company_name":"VOLITIONRX LTD","filed_at":"2023-03-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.641292+00:00","generated_at":"2026-06-18T02:42:08.891562+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"VolitionRx FY22 revenue $300k, cash $10.9M; Heska deal advances with $10M upfront","bullets":["Revenue $0.3M, up 240% YoY; net cash used in operations $15.3M ($1.3M/month).","Cash & equivalents $10.9M at Dec 31, 2022; raised ~$8.0M net in Feb 2023 offering.","Heska agreement: $10M upfront received, up to $18M milestones; IDEXX launched Nu.Q Vet test.","Nu.Q NETs CE marked; FDA Breakthrough Device application expected H1 2023.","34 patent families, 97 granted patents; capital market day set for May 11, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-23-001496","json":"https://secwatch.observer/filing/0001477932-23-001496.json","markdown":"https://secwatch.observer/filing/0001477932-23-001496.md","text":"https://secwatch.observer/filing/0001477932-23-001496.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/93314/000147793223001496/0001477932-23-001496-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/93314/000147793223001496/vnrx_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T02:42:08.891562+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a9a0baf284167f4601d8ad10e52cb47709538034","claim":"VOLITIONRX LTD reported the full fiscal year ended December 31, 2022 results: revenue approximately $300,000.","evidence_excerpt":"$8.0 million in net cash (before deducting offering expenses payable by Volition) through an underwritten public offering of its common stock. · Recorded approximately $300,000 in revenue in 2022, up 240% over the prior year. · Received a $10 million upfront payment on signing the Heska Licensing and Supply Agreement. · During 2022, strengthened its","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/93314/000147793223001496/0001477932-23-001496-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full fiscal year ended December 31, 2022"},{"label":"Revenue","value":"approximately $300,000"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}